(UroToday.com) The 2022 EAU Section of Oncological Urology (ESOU) Annual Meeting included a session on the early detection and personalized management of testis cancer and a presentation by Dr. Sia Daneshmand discussing the role of retroperitoneal lymph node dissection (RPLND) in stage II seminoma. Chemotherapy or radiotherapy are standard treatments for stage II seminoma, though they are associated with significant long-term treatment-related toxicities. Long-term morbidity from chemotherapy and radiotherapy is real, as these are young patients with excellent cure rates thus potentiating cumulative toxicities. These toxicities may include cardiac events, secondary cancers (hematologic and solid tumors), metabolic syndrome, bleomycin-induced pulmonary injury, infertility, neurotoxicity, tinnitus, and increased risk of suicide. So, is there a treatment that can reduce long-term morbidity?